These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7955749)

  • 21. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
    Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
    J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bowel perforation associated with intraperitoneal chromic phosphate instillation.
    Proctor J; Doering D; Barnhill D; Park R
    Gynecol Oncol; 1990 Jan; 36(1):125-7. PubMed ID: 2295443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients.
    Makhija S; Spanos WJ; Day TG; Doering D
    Gynecol Oncol; 1996 Oct; 63(1):85-8. PubMed ID: 8898174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative use of radioactive phosphorus in stage I ovarian carcinoma.
    Alderman SJ; Dillon TF; Krummerman MS; Phillips BP; Chung AF
    Obstet Gynecol; 1977 Jun; 49(6):659-62. PubMed ID: 865728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
    Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
    Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy.
    Cabrini RL; Ubios AM; Silberman FS
    J Bone Joint Surg Am; 1995 May; 77(5):807-8. PubMed ID: 7744908
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals.
    Creasman WT; Disaia PJ; Blessing J; Wilkinson RH; Johnston W; Weed JC
    Am J Obstet Gynecol; 1981 Dec; 141(8):921-9. PubMed ID: 7315922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant internal hepatic radiotherapy using colloidal 32P chromic phosphate in colorectal cancer.
    Kim JY; Bom HS; Kim YJ; Choi W
    Radiat Med; 1990; 8(6):246-9. PubMed ID: 2093946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneoscintigraphy in detection of improper placement of peritoneal catheter into bowel lumen prior to chromic phosphate P-32 therapy. A case report.
    Neutze J; Van Nostrand D; Major W
    Clin Nucl Med; 1985 Nov; 10(11):777-9. PubMed ID: 4075668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromic phosphate therapy in carcinoma of the ovary.
    Goodman A; Bornstein L; Ball H; Smith DM; Bankoff M
    J Am Coll Surg; 1994 Oct; 179(4):401-6. PubMed ID: 7921388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioactivity in breast milk after intraperitoneal chromic phosphate for the treatment of early ovarian cancer.
    Carlson JA; Jose B; Sharma SC; Osborne RP
    Am J Obstet Gynecol; 1983 Dec; 147(7):840-1. PubMed ID: 6650612
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose estimation to the infant from breast milk following intraperitoneal administration of chromic phosphate 32P for the treatment of early ovarian cancer.
    Sharma SC; Osborne RP; Jose B; Carlson JA
    Health Phys; 1984 Sep; 47(3):452-4. PubMed ID: 6500947
    [No Abstract]   [Full Text] [Related]  

  • 33. The measurement of radiation doses from P32 chromic phosphate therapy of the peritoneum using SPECT.
    Ott RJ; Flower MA; Jones A; McCready VR
    Eur J Nucl Med; 1985; 11(8):305-8. PubMed ID: 3878292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications in the use of intra-abdominal 32P for ovarian carcinoma.
    Spanos WJ; Day T; Abner A; Jose B; Paris K; Pursell S
    Gynecol Oncol; 1992 Jun; 45(3):243-7. PubMed ID: 1612499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioactive phosphorus and external radiation as an adjuvant to surgery for ovarian carcinoma.
    Julian CG; Inalsingh CH; Burnett LS
    Obstet Gynecol; 1978 Aug; 52(2):155-60. PubMed ID: 683654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy.
    Vider M; Deland FH; Maruyama Y
    J Nucl Med; 1976 Feb; 17(02):150-1. PubMed ID: 1245879
    [No Abstract]   [Full Text] [Related]  

  • 37. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
    Leichner PK; Rosenshein NB; Leibel SA; Order SE
    Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 32P following negative second-look laparotomy for epithelial ovarian cancer.
    Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
    Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites.
    Balink H; Sijmons EA; Zonnenberg BA; De Klerk JM
    Clin Nucl Med; 2003 Jul; 28(7):545-7. PubMed ID: 12819405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peritoneal fluid cytology in endometrial cancer: its significance and the role of chromic phosphate (32P) therapy.
    Heath R; Rosenman J; Varia M; Walton L
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):815-22. PubMed ID: 3182321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.